RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION

BACKGROUND: Low-grade gliomas (LGGs; WHO grade II) are incurable and ultimately progress to high-grade gliomas. The current treatment options are surgery followed by observation (“watch and wait”) for patients with lower risk for disease progression or postoperative chemoradiotherapy (high-risk popu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mellinghoff, Ingo, van den Bent, Martin, Clarke, Jennifer, Maher, Elizabeth, Peters, Katherine, Touat, Mehdi, de Groot, John, De La Fuente, Macarena, Arrillaga-Romany, Isabel, Wick, Wolfgang, Ellingson, Benjamin, Schoenfeld, Steven, Liu, Hua, Le, Kha, Lu, Min, Steelman, Lori, Hassan, Islam, Pandya, Shuchi, Wen, Patrick, Cloughesy, Timothy
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Randomized Trials in Development
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651526/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.810
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados